BIO Europe 2025

Last week our CEO Jan Thirkettle joined fellow neuroscience leaders at #BIOEUROPE2025 for a lively panel discussion on what’s next in tackling major CNS disorders.

These conversations are key as we advance our MISBA® platform technology to translate innovative science into meaningful treatments for patients with neurodegenerative diseases.

Thank you to EBD Group’s #BIOEurope for hosting this insightful discussion.

#HarnessTherapeutics #NeurodegenerativeDiseases

Our programmes

Huntington's Disease

ALS and Alzheimer's

Our news

October 2025

Harness Therapeutics Announces Launch of MISBA® Duo Platform and Research Collaboration with Ono Venture Investment

Read more

June 2025

Harness Therapeutics Publishes HTT CAG Repeat Sizing Methodology Code on GitHub

Read more

February 2025

Harness Therapeutics to Present Nanopore Sequencing Data for Detecting CAG Expansion in the Huntingtin Gene at CHDI Huntington’s Disease Therapeutics Conference

Read more

January 2025

Harness Therapeutics appoints Dr Heather Preston as Chair and secures new funding from Ono Venture Investment to accelerate delivery of transformational neurodegeneration pipeline

Read more